Tag: ironwood pharmaceuticals

October 30, 2019

Cyclerion’s Praliciguat Misses Phase 2 Endpoints, Shares Tumble

Shares of Cyclerion Therapeutics fell nearly 80 percent after it announced that its Phase 2 trials did not meet their...
August 13, 2019

Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ironwood Pharmaceuticals (NASDAQ:IRWD) has announced a US GI disease education and promotional agreement for Alnylam’s givosiran...
August 21, 2018

Approval of Linzess Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation

Astellas Pharma (TSE:4503) and Ironwood Pharmaceuticals (Nasdaq:IRWD) announced that approval has been obtained in Japan for the guanylate cyclase-C receptor...
July 16, 2018

Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C

Ironwood Pharmaceuticals (NASDAQ:IRWD) has announced the initiation of a Phase IIIb clinical trial evaluating the efficacy and safety of linaclotide...
June 8, 2018

Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease

Ironwood Pharmaceuticals (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...